Company research

NUWE · NASDAQ

Nuwellis Inc

Healthcare · Medical Devices

$5.78

+2.12%

Close on Oct 29, 2026

Research data through 2026-10-29

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Free research · no account required

Pro Investor Academy research

Research data through Oct 29, 2026. Research is updated periodically, not in real time.

Quality

53

of 100 · stored research reading

Stored Quality research reads 53 of 100, a middle-of-the-universe reading. The measurements behind it are mixed.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

How this is measured

Fundamental Momentum

Deteriorating

35

of 100 · stored research reading

Stored Fundamental Momentum research reads 35 of 100. Stored measurements classify recent reported fundamentals as deteriorating. This describes reported financial change already disclosed, with no forward-looking claim.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

How this is measured

Capital Returns

Weak

5

of 100 · stored research reading

Stored Capital Returns research reads 5 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 1026.7% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

How this is measured

Investor intelligence

What Investor adds for NUWE

The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.

Investor

See how this company ranks.

Unlock its Pro Investor Score and ranking across the research universe.

7 days · No credit card required

Investor

Understand the risk before you invest.

Unlock Risk Intelligence, Price Risk, and Market Confirmation.

7 days · No credit card required

Investor

Know why, not just what.

Unlock the Pro Research Brief with What Changed & Why, research history and tensions.

7 days · No credit card required

Investor

See what professional investors are reporting.

Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.

7 days · No credit card required

Investor

Ask the research.

Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.

7 days · No credit card required

Investor

Keep researching after today.

Save companies and monitor how their research changes over time.

7 days · No credit card required

Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.

Want to know what qualified today?

Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

In the company’s own words

What this company does

Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the "Aquadex System"). The Aquadex SmartFlow system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

Please note that selected authors in the citations below are either current consultants to the Company or were previously compensated consultants. Each author typically is required to disclose any actual or potential conflicts of interest at the time they submitted their written manuscript to the potential publication. Dr. Sean Pinney for example, was the principal investigator under the Company’s former REVERSE-HF heart failure clinical study. Additionally, Dr. Maria Rosa Costanzo, joined the Company’s Board of Directors in September 2019, though many of her cited publications preceded her membership on the Board of Directors. She resigned from the Board of Directors on January 21, 2026, which was not the result of any disagreement with Nuwellis regarding its operations, policies, or practices. Since joining the Company’s Board, Dr. Costanzo has declined any equity ownership in the Company, although she has accepted cash remuneration for her Board and Committee participation.

Fluid overload, also known as hypervolemia, is a condition in which there is too much fluid in the blood, vital organs, and interstitial space, and generally refers to the expansion of the extracellular fluid volume. Although the body does need some amount of fluid to remain healthy, too much can cause an imbalance and damage to an individual’s health. 1

The signs and symptoms of fluid overload are not always the same in each patient and may vary. However, possible signs and symptoms of fluid overload include pulmonary edema/pleural effusion, peripheral edema, anasarca (swelling of the skin) ascites, jugular vein distention and dyspnea. 2 Medical conditions or diseases where excess fluid accumulates in the body are heart failure, kidney failure, nephrotic syndrome, cirrhosis, and burn injuries/trauma. Individuals may also suffer from temporary fluid overload following certain surgical procedures, such as cardiac surgery. 3 The diagnosis of fluid overload can be made through a variety of tests/exams such as a physical exam (weight, presence of pulmonary rales, and edema), blood chemistry, natriuretic peptides, liver enzymes, hemoglobin and hematocrit, blood volume analysis, and/or bioimpedance analysis. 4 Fluid overload has a significant association with the combined events of death, infection, bleeding, arrhythmia, and pulmonary edema 5 and is a leading cause of hospital readmissions with patients suffering from heart failure and patients following cardiac surgery. 6

Quoted from the business section of this company’s 10-K filed March 11, 2026. Read the filing

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.